Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

[en] Basal cell carcinomas (BCCs) are the most frequent human cancer. Over 90% of all BCCs have a mutation in patched homologue 1 (PTCH 1) or smoothened (SMO), two conducting proteins of the Hedgehog (Hh) pathway. They rarely progress deeply and metastasize; however, if they do, these advanced BCC become amenable to treatment by inhibiting the Hedgehog and the P13K–mTOR pathways. Such innovative drugs include vismodegib, cyclopamine, itraconazole, everolimus and a few other agents that are in early clinical development.

Disciplines :

Dermatology

Author, co-author :

FRANCHIMONT, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Hermanns-Lê, Trinh ; Université de Liège - ULiège > Département des sciences cliniques > Dermatopathologie

PAQUET, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Herfs, Michael ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

Publication date :

2015

Journal title :

Future Oncology

ISSN :

1479-6694

eISSN :

1744-8301

Publisher :

Future Medicine Ltd

Volume :

Pages :

2997-3002

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 January 2014

Statistics

Number of views

203 (27 by ULiège)

Number of downloads

13 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Uhoda I, Quatresooz P, Fumal I et al. Updating trends in cutaneous cancers in south-east Belgium. Oncol. Rep. 12, 111-114 (2004).
Dummer R, Karpova MB, Barysch MJ. Basal cell carcinomas: molecular abnormalities and molecularly targeted therapies. Expert Rev. Dermatol. 4, 355-369 (2009).
Dreier J, Felderer L, Barysch M et al. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin. Pharmacother. 14, 1307-1318 (2013).
Tang JY, Marghoob AA. Emerging treatments and signalling pathway inhibitors. Semin. Cutan. Med. Surg. 30, S14-S18 (2011).
Kakanj P, Reuter K, Séquaris G et al. Indian Hedgehog controls proliferation and differentiation in skin tumorigenesis and protects against malignant progression. Cell Rep. 4, 340-351 (2013).
Dubey AK, Dubey S, Handu SS et al. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma. J. Postgrad. Med. 59, 48-50 (2013).
Xie J. Molecular biology of basal and squamous cell carcinomas. Adv. Exp. Med. Biol. 624, 241-251 (2008).
Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
Epstein EH. Basal cell carcinomas: attack of the Hedgehog. Nat. Rev. Cancer 8, 743-754 (2008).
Xie J, Murone M, Luoh SM et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998).
Aszterbaum M, Rothman A, Johnson RL et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110, 885-888 (1998).
Tang JY, Mackay-Wiggan JM, Aszterbaum M et al. Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366, 2180-2188 (2012).
Piérard GE, Piérard-Franchimont C, Léonard B, Delvenne P. The MAP kinase cascade. A key target for treatments in skin cancerology. Rev. Med. Liège 68, 650-654 (2013).
Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer. Am. J. Health Syst. Pharm. 70, 1033-1038 (2013).
Sekulic A. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N. Engl. J. Med. 366, 2171-2179 (2012).
Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur. J. Dermatol. 14, 96-102 (2004).
Kim J, Tang JY, Gong R et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17, 388-399 (2010).
Eibenschutz L, Colomba MD, Catricalà C. Everolimus for compassionate use in multiple basal cell carcinomas. Case Report Dermatol. Med. 2013, 604301 (2013).
Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch. Dermatol. 148, 1324-1325 (2012).
Lauth M, Bergstrom A, Shimokawa T et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl Acad. Sci. USA 104, 8455-8460 (2007).